Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership

被引:131
作者
Ryan, Patrick B. [1 ,2 ,3 ]
Madigan, David [2 ,4 ]
Stang, Paul E. [1 ,2 ]
Overhage, J. Marc [2 ,5 ,6 ]
Racoosin, Judith A. [2 ,7 ]
Hartzema, Abraham G. [2 ,8 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev LLC, Titusville, NJ USA
[2] Fdn Natl Inst Hlth, Bethesda, MD USA
[3] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC USA
[4] Columbia Univ, Dept Stat, New York, NY USA
[5] Indiana Univ Sch Med, Indianapolis, IN USA
[6] Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA
[7] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[8] Univ Florida, Coll Pharm, Gainesville, FL USA
基金
美国国家卫生研究院;
关键词
product surveillance; postmarketing; pharmacoepidemiology; epidemiologic methods; causality; electronic health records; adverse drug reactions; CLINICAL-TRIALS; CASE-CROSSOVER; SURVEILLANCE; SCIENCE; DESIGNS;
D O I
10.1002/sim.5620
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Expanded availability of observational healthcare data (both administrative claims and electronic health records) has prompted the development of statistical methods for identifying adverse events associated with medical products, but the operating characteristics of these methods when applied to the real-world data are unknown. Methods: We studied the performance of eight analytic methods for estimating of the strength of association-relative risk (RR) and associated standard error of 53 drugadverse event outcome pairs, both positive and negative controls. The methods were applied to a network of ten observational healthcare databases, comprising over 130 million lives. Performance measures included sensitivity, specificity, and positive predictive value of methods at RR thresholds achieving statistical significance of p < 0.05 or p < 0.001 and with absolute threshold RR > 1.5, as well as threshold-free measures such as area under receiver operating characteristic curve (AUC). Results: Although no specific method demonstrated superior performance, the aggregate results provide a benchmark and baseline expectation for risk identification method performance. At traditional levels of statistical significance (RR > 1, p < 0.05), all methods have a false positive rate >18%, with positive predictive value <38%. The best predictive model, high-dimensional propensity score, achieved an AUC = 0.77. At 50% sensitivity, false positive rate ranged from 16% to 30%. At 10% false positive rate, sensitivity of the methods ranged from 9% to 33%. Conclusions: Systematic processes for risk identification can provide useful information to supplement an overall safety assessment, but assessment of methods performance suggests a substantial chance of identifying false positive associations. Copyright (c) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:4401 / 4415
页数:15
相关论文
共 23 条
[1]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[2]   Does this patient have strep throat? [J].
Ebell, MH ;
Smith, MA ;
Barry, HC ;
Ives, K ;
Carey, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (22) :2912-2918
[3]  
Harman D, 1996, P 4 TEXT RETR C TREC, P30
[4]   Should we use a case-crossover design? [J].
Maclure, M ;
Mittleman, MA .
ANNUAL REVIEW OF PUBLIC HEALTH, 2000, 21 :193-221
[5]   Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA) [J].
Martin, BJ ;
Finlay, JA ;
Sterling, K ;
Ward, M ;
Lifsey, D ;
Mercante, D ;
Jainto, JM ;
Martin, L ;
Rayford, W .
PROSTATE CANCER AND PROSTATIC DISEASES, 2004, 7 (02) :132-137
[6]  
Noren N, 2010, DATA MIN KNOWL DISC, V20, P361
[7]   Validation of a common data model for active safety surveillance research [J].
Overhage, J. Marc ;
Ryan, Patrick B. ;
Reich, Christian G. ;
Hartzema, Abraham G. ;
Stang, Paul E. .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2012, 19 (01) :54-60
[8]   Digital mammography [J].
Pisano, ED ;
Yaffe, MJ .
RADIOLOGY, 2005, 234 (02) :353-362
[9]   Evaluating medication effects outside of clinical trials: New-user designs [J].
Ray, WA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 158 (09) :915-920
[10]  
Rosenberg L, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P185